Search Results - "Papp, Kim"

Efficacy and Safety of CT‐P43, a Candidate Ustekinumab Biosimilar, in Moderate‐to‐Severe Plaque Psoriasis: 52‐Week Results From a Randomised, Active‐Controlled, Double‐Blind, Phase III Study.

Authors: Papp, Kim A. Jaworski, Janusz Kwiek, Bartlomiej et al.

Source: Dermatologic Therapy. 2/23/2026, Vol. 2026, p1-12. 12p.

Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHT.

Authors: Armstrong, April Papp, Kim A. Lebwohl, Mark et al.

Source: Dermatology & Therapy. Jan2026, Vol. 16 Issue 1, p585-603. 19p.

Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III Trials.

Authors: Papp, Kim A. Del Rosso, James Q. Lebwohl, Mark G. et al.

Source: Dermatology & Therapy. Dec2025, Vol. 15 Issue 12, p3733-3744. 12p.

Population Pharmacokinetic and Pharmacodynamic Modeling for the Prediction of the Extended Amlitelimab Phase 3 Dosing Regimen in Atopic Dermatitis.

Authors: Tiraboschi, Gilles Papp, Kim Bieber, Thomas et al.

Source: CPT: Pharmacometrics & Systems Pharmacology. Dec2025, Vol. 14 Issue 12, p2161-2172. 12p.

Time to Onset of Action for Biologics and Targeted Treatments in Psoriasis: Systematic Targeted Literature Review and Network Meta-Analysis.

Authors: Papp, Kim A. Vender, Ron Purdy, Kerri et al.

Source: Dermatology & Therapy. Sep2025, Vol. 15 Issue 9, p2615-2629. 15p.

Efficacy and safety of ME3183, an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasis.

Authors: Papp, Kim A. Armstrong, April W. Koresawa, Tomokazu et al.

Source: Journal of the European Academy of Dermatology & Venereology. Apr2026, Vol. 40 Issue 4, p610-616. 7p.

Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study.

Authors: Harris, John E Papp, Kim Ezzedine, Khaled et al.

Source: British Journal of Dermatology. May2026, Vol. 194 Issue 5, p971-973. 3p.

Seeing the Unseen: Molecular Visualization in Biology

Authors: Finnan, Jeff Taylor-Papp, Kim Duran, Mesut

Source: Learning & Leading with Technology. Dec-Jan 2004-05 32(4):24-27.

Peer Reviewed: N

Page Count: 5

Descriptors: Biology, Chemistry, Molecular Structure, High School Students, Computer Uses in Education

Access URL: https://www.iste.org

Systemic treatment of immune checkpoint inhibitor‐induced psoriasis: Inference‐based guidance.

Authors: Papp, Kim A. Puig, Luis Beecker, Jennifer et al.

Source: Journal of the European Academy of Dermatology & Venereology. Nov2025, Vol. 39 Issue 11, p1881-1894. 14p.

Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study.

Authors: Harris, John E Papp, Kim Ezzedine, Khaled et al.

Source: British Journal of Dermatology. Mar2026, Vol. 194 Issue 3, p591-593. 3p.

Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results.

Authors: Papp, Kim A. Lebwohl, Mark G. Puig, Lluís et al.

Source: American Journal of Clinical Dermatology. Sep2025, Vol. 26 Issue 5, p829-841. 13p.

Approach to the Assessment and Management of Adult Patients With Prurigo Nodularis: A Canadian Consensus.

Authors: Hong, H. Chih-ho Prajapati, Vimal H. Papp, Kim A. et al.

Source: Dermatologic Therapy. 5/8/2026, Vol. 2026, p1-8. 8p.

Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel.

Authors: Papp, Kim A. Melosky, Barbara Sehdev, Sandeep et al.

Source: Dermatology & Therapy. Apr2023, Vol. 13 Issue 4, p867-889. 23p.

Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry.

Authors: Gooderham, Melinda Papp, Kim A. Lynde, Charles et al.

Source: Dermatology & Therapy. Feb2023, Vol. 13 Issue 2, p535-553. 19p.

Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeks.

Authors: Blauvelt, Andrew Papp, Kim Trivedi, Mona et al.

Source: British Journal of Dermatology. May2025, Vol. 192 Issue 5, p826-836. 11p.

Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data.

Authors: Papp, Kim A. Gooderham, Melinda Dei-Cas, Ignacio et al.

Source: Dermatology & Therapy. Jan2023, Vol. 13 Issue 1, p269-283. 15p.

Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasis.

Authors: Papp, Kim A. Thoning, Henrik Gerdes, Sascha et al.

Source: Journal of Dermatological Treatment. Nov2022, Vol. 33 Issue 7, p3005-3013. 9p.

Efficacy and safety of proactive treatment with twice-weekly topical Cal/BD foam in patients with plaque psoriasis undergoing HPA-axis testing: a PSO-LONG subgroup analysis.

Authors: Papp, Kim Adamski, Zygmunt Guenther, Lyn et al.

Source: Journal of Dermatological Treatment. Jun2022, Vol. 33 Issue 4, p2297-2304. 8p.

Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel.

Authors: Papp, Kim A. Beecker, Jennifer Cooper, Curtis et al.

Source: Dermatology & Therapy. May2022, Vol. 12 Issue 5, p1073-1089. 17p.

Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1.

Authors: Griffiths, Christopher E. M. Papp, Kim A. Song, Michael et al.

Source: Journal of Dermatological Treatment. Mar2022, Vol. 33 Issue 2, p848-856. 9p.